[<sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT dual-modality imaging enhances precision of staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms].
<sup>68</sup>Ga-DOTATATE PET/CT imaging should be the primary choice for GEP-NEN patients. Additional ¹⁸F-FDG PET/CT imaging can potentially improve precision of staging and treatment decision-making for G2, G3 and NEC patients but provides virtually no clinical benefits for G1 NET patients.
Authors
- Li‐Lan Fu
- Hubing Wu (ORCID: https://orcid.org/0000-0002-7546-5430)
- Yanchao Huang
- Jian-er Tan
- Ying Tian (ORCID: https://orcid.org/0000-0001-9211-3130)
- Yin Zhang (ORCID: https://orcid.org/0000-0002-6761-2269)
- Li Chen (ORCID: https://orcid.org/0000-0001-7670-8062)
- Fei Xie (ORCID: https://orcid.org/0000-0002-3636-2682)
- Xiaoxiang Zhang (ORCID: https://orcid.org/0000-0002-0805-5749)
- Dong Ye
Institutions
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-06-20
- DOI
- https://doi.org/10.12122/j.issn.1673-4254.2025.06.10
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article